Object This pilot study evaluated the utility of 3 0 -deoxy-
Introduction
Standard imaging criteria for evaluating therapeutic response are based upon anatomical information according to response evaluation criteria in solid tumors (RECIST) guidelines [1] . These criteria, which are based solely on a reduction in tumor size, do not take advantage of cellular and molecular information now available through contemporary imaging methodologies. Importantly, since [11, 12] . Nonetheless, [ 18 F]-FLT PET may reflect important cellular and molecular events associated with response to therapy, such as elevated p27, a critical cell cycle inhibitor [13, 14] .
The epidermal growth factor receptor (EGFR, HER1, ErbB-1) is frequently over-expressed in colorectal cancer (CRC) and, as such, has become an important target for therapy in advanced CRC [15] . A number of small molecule inhibitors of EGFR tyrosine kinase inhibitors have been developed, and have shown promise in many settings such as mutant EGFR lung cancer [16] . However, trials of EGFR tyrosine kinase inhibitors have not been successful in CRC [17] . Treatment of CRC with monoclonal antibodies, such as cetuximab (Erbitux), has shown more promise clinically when used in patients with metastatic disease whose tumors express wild-type KRAS [18] [19] [20] . We have previously evaluated [ 18 F]-FLT PET to assess treatment response to cetuximab in preclinical [4] and clinical studies [8] . The goal of this pilot study was to evaluate [ 18 F]-FLT PET to predict treatment response in a phase II neoadjuvant clinical trial of cetuximab followed by combined cetuximab and chemoradiotherapy in patients with advanced rectal cancer.
Materials and methods

Patients
All studies were approved by the Vanderbilt Institutional Review Board (ClinicalTrials Identifier: NCT01207895). Written informed consent was obtained from the patients prior to patient enrollment. Patients with histologically confirmed wild-type KRAS-expressing rectal tumors were enrolled in a multi-center clinical trial investigating the benefits of adding cetuximab to standard neoadjuvant chemoradiotherapy (NCT01207895) at Vanderbilt University Medical Center. A summary of patient characteristics can be found in Table 1 . The study schema is shown in Fig. 1 0 -O-benzoyl-2 0 -deoxythymidine (ABX Advanced Biochemical Compounds) was added in DMSO and reacted for 10 min at 160°C. The benzoyl-protecting group was removed from the labeled intermediate by basic hydrolysis (0.25 mol/L NaOH, 50°C, 10 min). The reaction mixture was purified on a semi-preparative C-18 high-performance liquid chromatography column eluting with 10 % ethanol/ 10 mmol/L sodium phosphate buffer and sterilized by 0.2 lm membrane filtration. Radiochemical identity, purity, and specific activity were determined by analytic highperformance liquid chromatography. The [
18 F]-FLT product was obtained with average radiochemical purity of 98.3 % and specific activity of 345.5 TBq/mmol. Imaging was performed with an integrated PET/CT scanner (Discovery LS, GE Healthcare), consisting of a combined full-ring PET scanner (Advance NXi) and an eight-section helical CT scanner (Light Speed Plus). The CT was performed with 140 kV, 80 mA, a tube-rotation time of 0.8 s per rotation, a pitch of 1.675 mm/rotation, with CT slice thickness of 3.75 mm at intervals of 3.27 mm and a matrix of 512 by 512 pixels. The CT data were reconstructed with a slice thickness of 5.0 mm and a matrix of 512 by 512 pixels. Patients were allowed normal, quiet breathing during imaging. PET data sets were reconstructed iteratively using the ordered subsets expectation maximization (OSEM) algorithm with segmented attenuation correction (two iterations). PET images were up-interpolated by vendorprovided software to match the CT matrix for image fusion. Independent as well as co-registered images were displayed by using a vendor provided workstation (Xeleris; GE Medical Systems). Images were evaluated by a qualified nuclear medicine physician (RCW).
Immunohistochemistry
Biopsy samples were blocked in paraffin and sectioned prior to immunostaining for proliferation markers including Ki67, TK1, and p27. Five micrometer thick sections were incubated with primary monoclonal antibodies for Ki67 (Dako #M7240, 1:100 dilution), TK1 (Abcam #57757, 1:100 dilution) and p27 (Dako #M7203, 1:100 dilution). Briefly, tissues were deparaffinized, rehydrated, and antigen retrieval was performed using a citrate buffer solution (pH 6.0) applied for 15 min at 105°C followed by a 10 min cool down at room temperature. A solution of 3 % H 2 O 2 was used to eliminate endogenous peroxidase activity and then blocked with a serum-free protein blocking reagent for 20 min. For detection of primary antibodies, tissue sections were incubated for 60 min at room temperature at the dilutions noted above. Subsequently, 
System-HRP Labeled Polymer detection method. Staining was completed after incubation with a DAB substratechromogen solution. Stained samples were evaluated by a gastrointestinal pathologist (MKW) and imaged at high magnification for reproduction.
Tumor genotyping
DNA was extracted from paraffin-fixed, formalin-embedded samples from each patient enrolled in the study. Tumor genotypes were assayed from 20 ng DNA using the SNaPshot mutational profiling method which consists of multiplexed PCR, multiplexed single-base primer extension, and capillary electrophoresis [22] [23] [24] . The current assay was designed to detect 62 point mutations in 7 genes (Table S1 ). Briefly, PCR primers were pooled to amplify the target DNA, and PCR was performed using the following conditions: 95°C (8 min), followed by 40 cycles of 95°C (20 s), 58°C (30 s) and 72°C (1 min), and then a final extension of 72°C (3 min). Next, PAGE-purified primers were pooled together and multiplex single-base extension reactions were performed on Exo-SAP-it treated (USB) PCR products using the following conditions: 96°C (30 s), followed by 35 cycles of 96°C (10 s), 50°C (5 s), and 60°C (30 s). Extension products were applied to capillary electrophoresis in an ABI 3730 analyzer and the data were interpreted using ABI GeneMapper software (version 4.0). Human male genomic DNA (Promega) was used as a wild-type control. Spiking primers were mixed to create a pan-positive control mix for the assay.
Statistical methods
Statistical significance of data was evaluated using the nonparametric Wilcoxon Rank Sum (Mann-Whitney U) tests in GraphPad Prism 4. Data were considered significant if p \ 0.05. 18 F]-FLT uptake in rectal tumors was reduced in 3/4 patients by 20, 55, and 25 % in patients, but was elevated by 45 % in one patient relative to the pre-treatment scan (Fig. 3) . After combined cetuximab and chemoradiotherapy, [ 18 F]-FLT uptake in rectal tumors was reduced by over 70 % in all patients compared to the pre-treatment scans. Additionally, reduced [ 18 F]-FLT uptake was observed in the bone marrow in the final post-treatment scan consistent with radiotherapy [27] . Due to the nature of the rectal tumors, the longest dimension of the tumors could not be reliably measured by CT in these patients.
Results
Immunohistochemistry
Representative high-power fields of Ki67, p27, and TK1 IHC for tumor specimens evaluated in this study are shown in Figs. 4 and 5. At surgery, patient 1 demonstrated almost complete reduction in tumor volume, however, as a very small number of tumor cells were histologically detected, the patient was classified as a pathological partial response (PR) to therapy. As patients 2-5 showed pathological complete response (CR) to therapy, no tumor tissue was available to analyze following combined cetuximab and chemoradiotherapy (Table 1) . In all patients, prominent Ki67 IHC staining was observed in pre-treatment biopsies. Reduced Ki67 was observed in the patients that demonstrated reduced [ 18 F]-FLT PET was not decreased following cetuximab, p27 levels were unchanged from baseline. In agreement with imaging, tumors exhibited robust TK1 immunoreactivity prior to treatment (Fig. 4) . In agreement with [ 
Tumor genotyping
No point mutations in KRAS, BRAF, AKT, PIK3CA, SMAD4, PTEN, or NRAS were detected in any tumor sample evaluated in this study (Table S2) .
Discussion
These studies mirror our previous clinical experience using [ 18 F]-FLT PET to predict pharmacodynamic response to cetuximab in Ménétrier's disease, a rare, premalignant, hyperproliferative disorder of the stomach [8] . We found that [ [11, 12] . Interestingly, however, this phenomenon was not observed with the rectal cancers evaluated in this study, which exhibited excellent signal to noise ratios. Our findings are in agreement with those of others [28, 29] 18 F]-FLT PET results, supported by Ki67 and p27 immunoreactivity, suggest that patient 3 did not experience an anti-proliferative benefit from cetuximab as monotherapy. However, this patient did ultimately benefit from the combined neoadjuvant treatment regimen. A notable limitation of the present study is the small sample size. Building upon the results presented here, we envision that in future studies employing similar regimens, postcetuximab [ 18 F]-FLT PET could potentially be incorporated as a non-invasive assay to predict those patients most likely to benefit from this drug prior to changes in tumor size ascertainable by anatomical imaging measures, such as CT.
At the conclusion of cetuximab, 5-FU, and radiation therapy, [ 18 F]-FLT uptake was reduced by at least 65 % from baseline in all four patients. Given that these patients had received cetuximab as well as chemoradiotherapy, it is not possible to be sure what specific role cetuximab played in modulating [ 18 F]-FLT PET at this third time point where an enhanced decrease in [ 18 F]-FLT uptake was observed relative to cetuximab alone. However, previous studies have shown that [ 18 F]-FLT PET was reduced following chemoradiotherapy in rectal tumors regardless of clinical outcome [28] . Notably, in this study, reduced [ 18 F]-FLT PET following chemoradiotherapy correlated with complete response, but the limited number of patients evaluated here does not warrant a definitive conclusion.
Conclusion
This pilot study represents the first clinical evaluation of [ 18 F]-FLT PET to predict response to neoadjuvant therapy that included EGFR blockade with cetuximab in patients with rectal cancer. We found that [ 18 F]-FLT PET accurately reflected proliferation in this setting and correlated with increased tumor levels of p27. Our results suggest that [ 18 F]-FLT PET is a promising imaging biomarker of treatment response in this setting and may provide insights into mechanism of response the targeted therapies.
